U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

,	-	Original programme	10000	COULT ICC OF TOOD, NO PERCENT	are required to respond to a delicerant	or anominator unless it contains a valo Civil	J CONDOCTIVATION		
	Substitute	for form 1449A/PTO			Complete if Known				
					Application Number	10/587,424			
				CLOSURE	Filing Date	July 26, 2006			
	STAT	EMENT B	YΑ	PPLICANT	First Named Inventor	Fan Lu			
					Art Unit	1657			
_		(Use as many she	ets as	necessary)	Examiner Name	Unassigned			
ĺ	Sheet	1	of	2	Attorney Docket Number	55340-311395			

U.S. PATENT DOCUMENTS								
Examiner	Cito	Document Number	Publication Dete MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Releven			
Initials *	Cite No. ¹	Number - Kind Code ² (if known)		Cited Document	Pesseges or Relevent Figures Appear			
	1.	US- 4,774,186	09/27/1988	Schaefer, Jr. et al.				
	2.	US- 6,579,714 B1	06/17/2003	Hirabayashi et al.				
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document Publication		Name of Patentee or	Pages, Columns, Lines, Where Relevant			
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶		

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cly and/or country where published.	T²					
	3.	ANG-LEE, M. et al., Herbal Medicines and Perioperative Care, JAMA, Vol. 286, No. 2, pp. 208-216, 2001.						
	4.	ESSER, M. et al., Cyanovirin-N Binds to gp120 to Interface with CD4-Dependent Human Immunodeficiency Virus type 1 Virion Binding, Fusion, and Interchity but does not Affect the CD4 Binding Site on gp120 or Soluble CD4- Induced Conformational Changes in gp120, Journal of Viriosogy, Vol. 73, No. 5, pp. 4360-4371, 1999.						
	5.	GOLAKOTI, T. et al., Structure Determination, Conformational Analysis, Chemical Stability Studies, and Antitumor Evaluation of the Cryptophycins. Isolation of the 18 New Analogs from Nostoc sp. Strain GSV 224, J. Am. Chem. Soc., Vol. 17p. p. 12030-12049, 1995.						
	6.	GONZALEZ, R. et al., Anti-Inflammatory Activity of Phycocyanin Extract in Acetic Acid-Induced Colitis in Rats, Pharmacological Research, Vol. 39, No. 1, pp. 55-59, 1999.						

Examiner Signature	Date Considered	

"EXAMINER: Initial if reterence considered, whether or not clastion is in conformance with MPEP 609. Draw line through citation If not in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique clatical notingation number (options): "See Kinds Codes of USPTO Patent Documents at www.use/so.gov or MPEP 901.01." Enter Office that issued the document, by the two-letter code (VIPPO Standard ST.3)." For applicant so part of the region of the Emperor must peccede the serial number of the patent document. "If of document unique support of the region of the patent of the patent document is "If of document unique support of the patent is a placed and comment unique "IVPO Standard ST.1 of passable." Applicant is to place a check make their Ellipsial harquings. Translation is attached

Translation is attached.
Translation is attached.
Translation of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 38 U.SC. 122 and 37 CFR 1.4. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from 1 both USFTO. The vill way depending upon the individual case, Any comments or the amount of time you require to complete this form and/or suppessions for reducing this budfor, should be sent to the Chief Information Officer, U.S. Potent and Chief.
Translation Clinic. U.S. Department of Commerce, P.O. Box V450, Alexandria, V.Z. 225114450, D.O. TO SEND FEES OF COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

$\overline{}$	Substitute for	or form 1449B/PTC			Complete if Known		
	INFORMATION DISCLOSURE				Application Number	10/587,424	
					Filing Date	July 26, 2006	
	STATI	EMENT B	ΥA	PPLICANT	First Named Inventor	Fan Lu	
					Art Unit	1657	
	(Use as many sheets as necessary)				Examiner Name	Unassigned	
C	Sheet	2	of	2	Attorney Docket Number	55340-311395	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue no.				
	7.	JAKI, B. et al., New Antibacterial Metabolites from the Cyanobacterium Nostoc Commune (EAWAG 122b), J. Nat. Prod., Vol. 63, pp. 1283-1285, 2000.			
	8.	HUANG, Z. et al., Studies on Polysaccharides from Three Edible Species on Nostoc (Cyanobacteria) with Different Colony Morphologies: Comparison of Monosaccharide Compositions and Viscosities of Polysaccharides from Field Colonies and Suspension Cultures, J. Phycol., Vol. 34, pp. 982-988, 1998.			
	9.	LIU, X. et al., Cell Differentiation and Colony Alteration of an Edible Terrestrial Cyanobacterium Nostoc Flagelliforme, in Liquid Suspension Cultures, Folia Microbiol, Vol. 48, No. 5, pp. 619-626, 2003.			
	10.	MUNDT, S. et al., Blochemical and Pharmacological Investigations of Selected Cyanobacteria, Int. J. Environ. Health, Vol. 203, pp. 327-334, 2001.			
	11.	MURAKAMI, M. et al., Microvindins, Elastase Inhibitors from the Cyanobacterium Nostoc Minutum (NIES-26), Phytochemistry, Vol. 45, No. 6, pp. 1197-1202, 1997.			
	12.	de PHILIPPIS, R. et al., Exocellular Polysaccharides from Cyanobacteria and their Possible Applications, FEMS microbiology Reviews, Vol. 22, pp. 151-175, 1998.			
	13.	PICCARDI, R. et al., Bioactivity in Free-Living and Symbiotic Cyanobacteria of the Genus Nostoc, Journal of Applied Phycology, Vol. 12, pp. 543-547, 2000.			
-	14.	QIU, B. et al., Distribution and Ecology of the Edible Cyanobacterium Ge-Xian-Mi (Nostoc) in Rice Fields of Hefeng County in China, Journal of Applied Phycology, Vol. 14, pp. 423-429, 2002.			
	15.	SCHERER, S. et al., Novel Water Stress Protein from a Desiccation-Tolerant Cyanobacterium, Journal of biological Chemistry, Vol. 284, No. 21, pp. 12546-12553, 1989.			
	16.	SMITH, C. et al., Cryptophycin: A New Antimicrotubule Agent Active against Drug-Resistant Cells, Cancer Research, Vol. 54, pp. 3779-3784, 1994.			
	17.	TAKENAKA, H., Safety Evaluation of Nostoc Flagelliforme (Nostocales, Cyanophyceae)) as a Potential Food, Food and Chemical Toxicology, Vol. 36, pp. 1073-1077, 1998.			
	18.	Patent Cooperation Treaty, International Search Report, International Application No. PCT/US05/03314, mailed October 2, 2007.			
	10.	October 2, 2007.			

Examiner Signature	Date Considered	
Olgitaluie	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to lake 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450